To assess implementation rates of the consensus plans made at the uro-oncology multidisciplinary meeting (MDM) of an Australian tertiary centre, and analyse obstacles to implementation.
Introduction
A patient with cancer will need input from a range of medical specialties and allied health professionals. Such multidisciplinary care (MDC) allows clinicians with a range of expertise to collaborate in patient care. This brings to bear a broader knowledge base and promotes balanced decision making [1] . MDC may also enhance patient understanding and improve survival [2] [3] [4] .
Formal provision of such inter-disciplinary care may be variously structured as multidisciplinary meetings (MDM), multidisciplinary care clinics, and tumour boards [1] . MDC has existed in the USA for >50 years [5] , and has since been endorsed in the UK [6] , Europe [7] , Africa [8] , and Asia [9] . In Australia, MDC became government policy in 1997 [10] and is now well recognised as best practice [11, 12] .
The global movement towards MDC is also true of urological malignancies [2, 3, [13] [14] [15] [16] [17] [18] . Recent research has focused on the impact of these uro-oncology MDMs on patient care. Studies at our centre [19] and elsewhere [17, [20] [21] [22] reveal that MDMs change 2-32% of management plans.
However, there is scant evidence regarding the rate at which these plans are then implemented [15, 23] . Literature on the Australian experience is limited [24] , but suggests high rates of adherence. We therefore aimed to assess rates of deviation from the consensus plans of our institutional uro-oncology MDM.
Methods
Our institutional uro-oncology MDMs have been held weekly since 2007 [19] . Patients are referred for discussion from both Austin Health and private practices. These cases are presented before an audience of urologists, medical oncologists, radiation oncologists, pathologists, radiologists, nuclear medicine physicians, urology nurse specialists, and trainees from the various specialties.
With institutional Human Research Ethics Committee approval (LNR/16/Austin/333), all cases discussed at the MDM between 1 January and 30 June 2015 were enrolled. This period was chosen to allow sufficient follow-up to ascertain whether the MDM plan had been implemented, even allowing for delays.
Urological oncological procedures performed during the study period were also collated to assess the proportion discussed at MDMs. Cases of prostate biopsy were reviewed, and patients with benign histology were excluded. The proportion of patients undergoing an oncological procedure who were subsequently discussed at a MDM was examined overall and by tumour type.
The consensus plan developed for each patient at the MDM was determined from a database prospectively maintained through the North Eastern Melbourne Integrated Cancer Service. Hospital records were interrogated to assess whether MDM consensus plans were implemented within 3 months and reasons for non-implementation. MDM consensus plans could involve one or more recommendations. In addition to surveillance by that specialty, a plan of referral to the outpatient clinic of medical oncology, radiation oncology or urology could involve recommendation to commence chemotherapy or hormonal therapy, radiotherapy or surgery, respectively. All aspects of the plan needed to occur within 3 months for implementation to be assessed as complete.
Results

Patients
In all, 202 patients were discussed at the uro-oncology MDM during the enrolment period, of whom 32 (15.8%) were female. The median (interquartile range [IQR]) age was 68 (59-74) years and 50 (24.8%) patients had metastasis. In order of frequency, patients discussed at MDM had malignancies of the prostate (86 patients), bladder (47), kidney (46) and testes (17) . Six patients had tumours of other urological organs, including the penis or adrenals, or had urological organs invaded by tumours of other viscera.
Capture of eligible cases
Within the enrolment period, 291 oncological urological procedures producing histological specimens were performed. Excluding 51 cases of prostate biopsy with benign histology, 240 patients were eligible for presentation at the MDM, of whom 160 (66.7%) were discussed. Uro-oncological procedures, categorised by tumour type and procedure, are outlined in Table 1 . This shows that almost all newly diagnosed uro-oncology patients are discussed at a MDM, with the exceptions being bladder tumours resected cystoscopically (around one-third), prostate cancer treated by radical prostatectomy (just over half), and renal tumours treated by nephrectomy (about three-quarters).
MDM plans
MDM consensus plans could involve one or more recommendations per patient, with only integer values possible. Among the 202 patients discussed, their plans comprised a total of 297 recommendations, representing on average 1.5 recommendations per patient [median (IQR) 1 (1-2)]. Plans most commonly directed patients towards further specialist consultation. There were 216 such referrals in total, representing 72.7% of all plans. In all, 105, 56 and 54 patients were referred to the outpatient clinics of urology, medical oncology, and radiation oncology, respectively. For eight patients, their follow-up occurred in private practice or with their regional public hospital service. Surgery was planned for 36 patients. Three patients were recommended for enrolment in clinical trials at Austin Health. Thirteen patients had other recommendations in their consensus plans, distinct from previous categories. These consisted of seven patients referred for consultation with a specialty not present at the uro-oncology MDM, three patients recommended for nephrostomy tube insertion or change, two patients requiring re-examination of their histology by a pathologist, and one patient booked for liver biopsy. Full details on patient demographics, tumour types, and MDM consensus plans are summarised in Table 2 .
Implementation of MDM plans
MDM consensus plans failed to be fully implemented within a 3 month time-frame in 18 (8.9%) patients. Reasons are given in Table 3 , and included system delays in five patients, patient deterioration or comorbidities in four, patient (Table 4 ) [17, [18] [19] [20] [21] [22] . However, there is a paucity of literature about how frequently these consensus plans are enacted.
The outcomes of an Italian prostate cancer MDM over 6 years were published by Magnani et al. [15] , who reported that 6% of consensus plans were changed subsequently during patient-clinician consultations. Patient numbers were not stated. De Ieso et al. [23] detailed the decision outcomes of 551 patients with solid tumours and lymphoma discussed in an MDM in the UK. Divergence from the MDM consensus plan occurred in 48 (8.7%) cases. Implementation rates from patients presented over 3 months at a selection of surgical oncology MDMs at our institution were published previously [24] ; for the 160 patients with evaluable data, the retrospective audit found only 5% of plans were not enacted.
The present study represents the largest assessment in Australasia of the implementation rates of consensus plans formulated in an MDM, uro-oncological or otherwise. The deviation rate of 8.9% is similar to the small number of similar existing studies. The causes for altering the plans are also similar (Table 3) . A small deviation rate is to be expected, as during the time taken to present the patient at a MDM and then discuss this plan in outpatient clinic with the patient, there may be changes in patient preference, health or the clinical scenario.
Continued efforts are required to minimise MDM nonimplementation rates and most efficiently use meeting time, as the administration and staffing costs of MDMs are significant, and may exceed AUD$15 000 per month [23] . Referrals to the MDM must be economical. Inefficient referral of patients with less complex clinical scenarios [18, 21] or incomplete staging information [15, 21, 24 ] is well *All delayed plans in our study were eventually implemented. n/a: not applicable. documented. Furthermore, in health systems with multiple MDMs of overlapping scope or arranged in a hierarchy, patients may be discussed at up to five separate meetings [23] . Strategies to improve the efficiency of MDM referral should therefore include institutional protocols for the management of straightforward cases and efforts to increase the accuracy of presented patient data.
Increased involvement of allied health professionals during the MDM may further reduce non-implementation rates. Allied health professionals report often having useful information to add to MDM discussion about patient psychosocial state, but having difficulty in contributing, due to perceptions of lack of time or respect for their input [30] . Structured methods of regularly involving allied health staff in meeting dialogue may be beneficial.
Similarly, greater patient involvement may help reduce plan deviation due to causes found commonly in the present study such as system delays, patient preference, and unreported significant comorbidities. However, how best to involve the patient remains an area for debate [18, 31] . Australian governmental guidelines recommend patients with cancer 'participate as members of the multidisciplinary team in treatment planning' [32] . However, MDC exists in different formats across Australia, so the method of patient involvement varies.
Clinicians are often averse to patients being present during the MDM, due to concerns that it would be confronting for patients, provoke anxiety, constrain the dynamics of frank MDM discussion [30] , and be less comfortable for all parties than subsequent one-on-one discussion [14] . Testing these apprehensions, Choy et al. [33] involved 30 well-educated English speaking patients with breast cancer in postoperative MDM discussion of their cases, and compared their experience to matched patients who did not attend. Involved patients tended to feel better informed, had no measurable change in anxiety scores, and would recommend the experience to others. However, most clinicians reported that they had to modify their language, and did not find patient involvement to have a positive impact on the MDM. Considering this, the most appropriate approach may be greater efforts to understand patient wishes before the MDM, followed by the common practice, as currently structured at our institution [19] and elsewhere [3, 16, 17, 20, 23] , of patients consulting with clinicians and discussing MDM plans solely in one-on-one settings.
It is well accepted that not all patients with cancer require MDM discussion [33] . We found that 67% of patients undergoing a uro-oncological procedure demonstrating malignant histology were discussed at the MDM. This rate appears to strike a reasonable balance between the availability of MDM care and the provision of stream-lined protocol-driven care for straightforward cases. We have previously proposed selection criteria that may help guide the inclusion of patients in uro-oncology MDMs to maximise potential management impact [19] . These include need for multi-modal treatment, recurrent or metastatic disease, potential patient eligibility for a clinical trial, rare tumours, and cases with diagnostic uncertainty. Daily practice at our institution also includes many malignancies that do not meet these criteria, and are thus routinely managed in uro-oncology outpatient clinic, in accordance with evidence-based guidelines.
MDC remains relatively new in Australia and its reception amongst urologists has been mixed [34] . An effective multidisciplinary team will cross-refer patients to its constituent specialties. In a previous study [19] of our institution's uro-oncology MDM, published in 2014, 33% of MDM patients were cross-referred between specialties. An even greater proportion of inter-disciplinary referrals are evidenced in this more recent analysis. These findings should reassure those involved in the care of patients with urological malignancies of the growing commitment to MDC. This collaborative approach of urologists, and their fundamental role in common malignancies, such as prostate cancer, should also support future campaigns to raise public awareness of the profession [35] .
Effective discussion at MDMs requires thorough collection of patient information. These high-quality data may be suitable for national aggregation in existing national cancer registries, such as the newly founded Prostate Cancer Outcomes Registry-Australia and New Zealand [36] . Challenges to enrolling MDMs nationwide would include ethical considerations including distribution of patient information, perceived threat to clinical independence from national review, and administrative burden if automatic digital linkage were problematic. However, international experience has shown that such a system may hold great opportunities. These include harnessing national knowledge-base and the pooling of uncommon malignancies, enabling publication of both consensus protocols and population-scale studies, respectively [37] . An additional significant benefit may be greater adherence to evidence-based guidelines and subsequent improved patient outcomes [2, 4] .
Limitations of the present study include its retrospective nature, moderate size, and single-institution focus. Additionally, some malignancies will be discussed within the enrolment period but have their oncological procedure beyond it, which will affect the expected ratios of related procedures, such as transurethral resection of bladder tumour and cystectomy.
In summary, the present study shows that most urological oncology patients are managed with multidisciplinary input, and the rates of non-implementation of recommendations are low. Incremental improvement may stem from increasing 18 © 2017 The Authors BJU International © 2017 BJU International patient information accuracy and allied health involvement. MDMs may support national oncological registries, and their collegiality may benefit public awareness campaigns of relevant specialists for specific malignancies. Further studies are required to confirm and build on these findings.
